The third quarter of 2024 has been rewarding for equity investors, as the S&P 500 increased another 5% and has gained almost 20% year to date. Surprise, surprise, though, as value was the segment leader in the quarter. The S&P 500 Value Index advanced approximately 7% in the period, while the S&P 500 Growth Index edged only 3% higher. Leading sectors included Real Estate, Utilities, Financial, Healthcare and Industrials, while lagging sectors for the past three months included Information Technology and Energy. The average stock in the Argus Universe of Coverage rose almost 8% during the quarter, while the median stock increased 9%. The average BUY-rated stock rose 8.3%, while the average HOLD-rated stock gained 6.7%. Here are the top-10 and bottom-five performers from the Argus Universe in 3Q24.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.

Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer. The company has approximately 5,150 employees.